US/UK/Canada

Share

Pick a time period -
Tags ( Active)

BioStock: WntResearch updates after stopped study

Just under a month ago, WntResearch announced that it had not seen any clinically significant effect of Foxy-5 in the now completed NeoFox study. The work now revolves around securing as much value for the owners as possible. The company’s CEO, Per Norlén, recently provided a market update, and BioStock contacted him to get his thoughts on this.Read the full article at biostock.se : https://www.biostock.se/en/2024/10/wntresearch-updates-after-stopped-study/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

WntResearch provides an update on the work in progress to safeguard the interests of shareholders and company values

WntResearch today provides an update on the work to secure company values following the negative initial outcome analysis of the phase 2 study NeoFox. The company's drug candidate Foxy-5 showed no effect on tumors and lymph nodes as evaluated by CT, which therefore does not justify a continuation of the study. In order to safeguard the interests of the shareholders, the Board of Directors and management are working intensively on several parallel tracks where a goal is to complete a merger or a reverse acquisition.The Phase 2 clinical study NeoFox aimed to establish proof-of-concept for the

BioStock: WntResearch plummets after results

The initial results from the NeoFox clinical phase II study have arrived. The safety seems to be good, but unfortunately, Foxy-5 appears to have limited treatment effects. The stock plummeted on the news. BioStock contacted Per Norlén, CEO of WntResearch, for a comment.Read the full article at biostock.se : https://www.biostock.se/en/2024/09/wntresearch-plummets-after-results/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

WntResearch’s CEO to BioStock: “Aiming for an agreement”

WntResearch is approaching the first readout from the expansion part of the phase II study with Foxy-5 in colon cancer. In parallel, the company is working on business development where several potential partners are interested in taking part in the upcoming results, which are absolutely crucial for the project and the company: – We are getting closer to a decision for WntResearch and Foxy-5. It will definitely be an exciting autumn, CEO Per Norlén writes in the Q2 report.Read the full article at biostock.se : https://www.biostock.se/en/2024/08/

WntResearch presents ad hoc observations from the NeoFox study at ESMO GI

WntResearch announces that a poster on the previously communicated positive ad hoc observations from the ongoing clinical phase 2 study NeoFox, will be presented at ESMO Gastrointestinal Cancer Congress (ESMO GI), the leading European congress for gastrointestinal cancer held between June 26-29 in Munich, Germany.The poster presented at ESMO GI details ad hoc observations from 110 patients in the ongoing NeoFox study, indicating that a three-week pre-operative treatment with Foxy-5 rapidly reduces local tumour spread of colon cancer. Additionally, the poster includes new data on tumour (T)-

WntResearch’s CEO to BioStock: “If the effect is confirmed, there are good opportunities for licensing agreements next year”

In the Q1 report, Per Norlén writes his first CEO statement for WntResearch since taking office in March. The company’s focus right now is on the NeoFox study where recruitment is in full swing. – We will put most of our focus on patient recruitment and business development in the near future, says Per in a comment to BioStock.Read the full article at biostock.se : https://www.biostock.se/en/2024/05/wntresearchs-ceo-if-the-effect-is-confirmed-there-are-good-opportunities-for-licensing-agreements-next-year/ This is a press release from BioStock -

BioStock: WntResearch’s new CEO comments on his first month in the position

Development company WntResearch recently recruited the first patient for the expansion part of the ongoing phase II study, NeoFox. This coincided with Per Norlén’s first days at the helm of the company. BioStock contacted him to find out how he sees the potential of Foxy-5, and how he, with a long career as CEO of several biotech companies, wants to contribute to advancing the positions of the project.Read the full article at biostock.se : https://www.biostock.se/en/2024/03/wntresearchs-new-ceo-comments-on-his-first-month-in-the-position/ This is a press

Resigning WntResearch CEO tells BioStock: “It will be exciting to follow!”

Upon writing her last CEO comment in the company’s Q4 report, WntResearch’s resigning CEO Pernilla Sandwall talks about a “transformative” 2023 for the company. Based on the company releasing new data, updating their NeoFox trial and aquiring a new CEO, the labelling seems appropriate. BioStock reached out to Sandwall for a comment.Read the full article at biostock.se : https://www.biostock.se/en/2024/03/resigning-ceo-on-the-future-of-wntresearch-it-will-be-exciting-to-follow/ This is a press release from BioStock - Connecting Innovation & Capital. https://

WntResearch initiates collaboration with Business Sweden with the goal of establishing commercial partnerships for Foxy-5 in Japan and South Korea

WntResearch announces today that the company has initiated a collaboration project with Business Sweden with the aim of establishing one or more commercial partnerships for the drug candidate Foxy-5 with Japanese and South Korean companies.The collaboration takes place within the framework of Business Sweden's export project, which aims to introduce Swedish innovations to new international markets by promoting partnerships and networking, as well as providing financial support for research projects in small and medium-sized companies.    Business Sweden will assist WntResearch in

WntResearch continues to the next step in the phase 2 study NeoFox with the highest evaluated dose of Foxy-5

WntResearch announces today that the company, after a very fast patient recruitment, has been able to determine that the highest evaluated dose (8 mg/kg) of the drug candidate Foxy-5 will be used in the next step of the proof of concept study NeoFox. Approximately 80 patients with colon cancer will be treated in the second part of the study and an initial efficacy analysis is planned as early as the end of 2024.Previously reported ad hoc observations in patients with colon cancer indicate that the company's drug candidate Foxy-5 has a tumor-inhibiting effect already after three weeks of

WntResearch announces the last day for trading in BTU and the first day for trading in warrants series TO 7 and warrants series TO 8

During the period 15 – 29 January 2024, Wntresearch AB ("WntResearch" or the "Company") carried out a rights issue of units, consisting of shares and warrants series TO 7 and TO 8 (the "Rights Issue"). Through the Rights Issue, WntResearch has received approximately SEK 31.4 million before issue costs and, in the event of full exercise of all warrants issued, WntResearch may receive additional proceeds amounting to approximately SEK 26.9 million before issue costs, based on a maximum subscription price of SEK 0.12.The Rights Issue has now been registered with the Swedish Companies

WntResearch carries out a directed issue of units to underwriters in connection with the completed rights issue

Wntresearch AB (“WntResearch” or the “Company”) has completed the rights issue of units, consisting of shares and warrants series TO 7 and TO 8, resolved upon by the board of directors on 20 November 2023 and subsequently approved by the extraordinary general meeting on 22 December 2023 (the “Rights Issue”). In connection herewith, in accordance with the underwriting commitments that have been entered into and what has been previously communicated, a directed issue of units is carried out to those underwriters in the Rights Issue who have chosen to receive underwriting compensation in the

WntResearch publishes outcome in rights issue

The board of directors of Wntresearch AB (“WntResearch” or the “Company”) today announces the outcome of the rights issue of units that was announced on 20 November 2023 (the “Rights Issue”). In total 109,420,566 units, corresponding to approximately 54.6 percent of the Rights Issue, were subscribed for by exercise of unit rights, and 2,602,327 units, corresponding to approximately 1.3 percent of the Rights Issue, were subscribed for without unit rights. The Rights Issue is thus subscribed to a total of approximately 55.9 percent and no issue guarantees will need to be used. Through the

WntResearch's co-founder applies for subscription of additional units in the ongoing rights issue with a last day for subscription on 29 January 2024

Tommy Andersson, co-founder and board member of WntResearch AB ("WntResearch" or the "Company"), has applied for subscription of additional units in the rights issue that was announced through a press release on 20 November 2023 (the "Rights Issue"). In addition, several of the Company's existing larger shareholders have also announced their intention to subscribe for more units than what they have committed to in advance by agreement.Tommy Andersson has, through a company and without the support of unit rights, applied for additional subscription of units in the Rights Issue with SEK 118,

WntResearch publishes prospectus in connection with rights issue

The board of directors of Wntresearch AB (“WntResearch” or the “Company”) has prepared an EU Growth Prospectus (the “Prospectus”) in connection with the rights issue of units announced through a press release on 20 November 2023 (the “Rights Issue”). The Prospectus has today been approved and registered by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) and is available on the Company’s website.The Prospectus regarding the Rights Issue has been approved and registered by the Swedish Financial Supervisory Authority and is now available on WntResearch’s website, www.

Bulletin from the extraordinary general meeting in Wntresearch AB on 22 December 2023

Today, on 22 December 2023, an extraordinary general meeting was held in Wntresearch AB. A summary of the adopted resolutions follows below.Resolution on reduction of the share capital for loss coverage The meeting resolved in accordance with the proposal from the board of directors to reduce the share capital with SEK 8,000,000 for loss coverage, without withdrawal of shares. Through the resolution, the share capital is reduced from SEK 36,087,068.61 to SEK 28,087,068.61, whereby the share’s quota value is reduced from SEK 0.09 to approximately SEK 0.07. Resolution on amendment of

WntResearch continues to the second dose group in clinical proof of concept study of Foxy-5

WntResearch today announces that the safety evaluation from the first cohort in the dose-finding part of the proof-of-concept study NeoFox, support continued evaluation of the drug candidate Foxy-5 at an additional higher dose. After the most appropriate dose has been defined in the spring, approximately 80 patients with colon cancer will be treated. An initial efficacy analysis is planned based on data from 20 patients in active treatment and 20 patients in the control group."We are pleased that patient recruitment to the first dose group in the NeoFox study has been completed so quickly

WntResearch's scientific founder publishes study on WNT5A signaling in scientific journal

WntResearch announces today that a study describing WNT5A signaling and its mechanism of action has been published in the scientific journal Cells. The publication strengthens the hypothesis that Foxy-5, through its ability to mimic WNT5A signaling, can inhibit the spread of colon cancer. The study was led by Professor Tommy Andersson, co-founder of WntResearch, and his research group in collaboration with Professor Anita Sjölander's research group.In the study, the researchers examined WNT5A expression and its signaling in patients' colon cancer tissue, in various colon cancer cells and in

WntResearch’s CEO: “In a better position than ever”

Reporting its third quarter, WntResearch is focusing on the restart of the NeoFox study with Foxy-5. The first patient was recently enrolled in the redesigned study, where the next milestone will be a first readout when half of the patients have been treated. BioStock reached out to CEO Pernilla Sandwall to get her thoughts on the development during the quarter.Read the full article at biostock.se : https://www.biostock.se/en/2023/11/wntresearchs-ceo-in-a-better-position-than-ever/ This is a press release from BioStock - Connecting Innovation & Capital.

WntResearch carries out a rights issue of units of approximately SEK 56 million

The Board of Directors of Wntresearch AB ("WntResearch" or the “Company") has today, subject to subsequent approval by the extraordinary general meeting in the Company on 22 December 2023, resolved to carry out a rights issue of units, consisting of shares and warrants, with preferential rights for the Company’s existing shareholders (the "Rights Issue"). The Rights Issue is mainly intended to finance and complete the Company’s ongoing Phase 2 study NeoFox as well as continued clinical and regulatory development and intensified business development. In connection with the Rights Issue, the

WntResearch and Collective Minds Radiology sign agreement for quality assurance of clinical study

WntResearch and Collective Minds Radiology announce that the companies have signed an agreement to quality assure data reading in the ongoing phase 2 study of the drug candidate Foxy-5. The collaboration increases the precision of the evaluation of the treatment effect in the study.Collective Minds Radiology, CMRAD, is a healthtech company that has developed a cloud-based platform for research and healthcare purposes. The CMRAD platform will provide the base for central independent expert reading of diagnostic imaging performed in patients included in the study. The clinics will share

BioStock: WntResearch recruits first patient in restart of NeoFox

After receiving the green light for its redesigned study plan for NeoFox this summer, WntResearch have announced the recruitment of the first patient. The revised study is now officially underway with the first part expected to take about six months to complete. BioStock contacted CEO Pernilla Sandwall for a comment on this milestone.Read the article at biostock.se: https://www.biostock.se/en/2023/10/wntresearch-rekryterar-forsta-patienten-i-aterstarten-av-neofox/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

WntResearch has included the first patient in the redesign of the proof of concept study NeoFox with the drug candidate Foxy-5

WntResearch announced today that the first patient has been included in the redesign of the Phase 2 clinical trial NeoFox, which is a proof of concept study with the drug candidate Foxy-5. The first patient was recruited at a trial center in Barcelona, Spain.The Phase 2 clinical trial NeoFox is a proof of concept study in patients with colon cancer which was originally intended to include a two year follow-up period of the patients. Positive ad hoc observations generated in the study enabled the design to be adjusted, which provides great benefits in terms of time and cost savings. The new

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe